Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Share-based Compensation (2016 - 2025)

Abeona Therapeutics has reported Share-based Compensation over the past 15 years, most recently at $2.6 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.6 million for Q4 2025, up 30.9% from a year ago — trailing twelve months through Dec 2025 was $10.8 million (up 62.63% YoY), and the annual figure for FY2025 was $10.8 million, up 62.63%.
  • Share-based Compensation for Q4 2025 was $2.6 million at Abeona Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ABEO hit a ceiling of $2.8 million in Q2 2025 and a floor of $632000.0 in Q3 2022.
  • Median Share-based Compensation over the past 5 years was $1.7 million (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 3423.61% in 2021 and later plummeted 75.09% in 2022.
  • Abeona Therapeutics' Share-based Compensation stood at $2.0 million in 2021, then tumbled by 58.37% to $833000.0 in 2022, then soared by 81.75% to $1.5 million in 2023, then grew by 29.13% to $2.0 million in 2024, then soared by 30.9% to $2.6 million in 2025.
  • The last three reported values for Share-based Compensation were $2.6 million (Q4 2025), $2.7 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.